Summary
This content was automatically synthesized by Credo's AI models directly from the original source text.
AI summaries can make mistakes — double-check important details against the original source.
1 Sample Definition And Size
The meta-analysis included 23 randomized controlled trials with a combined sample size of 57,911 participants, assessing the safety of semaglutide compared to placebo across various patient populations and treatment durations.
2 Study Type
Meta-analysis
3 Conflicts Of Interest
The authors did not declare any conflicts of interest in the study.
4 Results Summary
The meta-analysis found that semaglutide was generally well-tolerated, with a low incidence of adverse events. The most common adverse events were gastrointestinal in nature, specifically nausea and vomiting. No significant differences were observed between semaglutide and comparator groups regarding cardiovascular adverse events, sudden cardiac death, adverse events leading to death, hypoglycemia, or new-onset neoplasms.